Nivolumab Combo Appears Tolerable in Poor Prognosis, Advanced Melanoma

Nivolumab Combo Appears Tolerable in Poor Prognosis, Advanced Melanoma

Publication date: Jul 09, 2023

The benefit of nivolumab/ipilimumab plus single-agent nivolumab for unresectable advanced melanoma with poor prognostic characteristics was .. .

Concepts Keywords
Clinical Advanced
Melanoma Agent
Poor Appears
Tolerable Benefit
Trials Characteristics
Combo
Ipilimumab
Melanoma
Nivolumab
Poor
Prognosis
Prognostic
Single
Tolerable
Unresectable

Semantics

Type Source Name
drug DRUGBANK Nivolumab
disease MESH Melanoma
drug DRUGBANK Ipilimumab
pathway KEGG Melanoma

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *